Spirit AeroSystems Holdings Inc (SPR) Stock News

CRISPR Therapeutics has transitioned to a commercial biotech with its approved gene-editing therapy Casgevy for blood disorders. The company has several promising pipeline candidates including CTX310 for cholesterol/triglycerides, zugo-cel for autoimmune diseases and blood cancers, and CTX611 as an anticoagulant. While significant clinical and commercial progress could drive substantial stock gains by 2030, investors face considerable risks including potential clinical trial failures and uncertain profitability economics for one-time gene-editing treatments.

Cathie Wood's ARK Invest purchased $3.4 million worth of CRISPR Therapeutics stock on consecutive trading days (Oct. 9 and Oct. 12), bringing her total holdings to $379.1 million. The investment reflects confidence in CRISPR's approved therapy Casgevy and promising pipeline candidates CTX-310 and CTX611, despite the stock declining 25% over the past year. CRISPR reported strong Q2 revenue growth of 151% year-over-year and maintains $2.36 billion in cash.

CRISPR Therapeutics AG (CRSP) declined 3.45% to $51.55, underperforming the S&P 500's 0.06% loss. Despite a 3.23% monthly gain, the stock faces headwinds. The company is expected to report an EPS of -$1.06 but projects significant revenue growth of 971.24% year-over-year. CRSP holds a Zacks Rank #2 (Buy) rating, though its industry ranks in the bottom 33% of all sectors.

The global animal model market is projected to grow from USD 2.02 billion in 2025 to USD 3.31 billion by 2034, expanding at a CAGR of 5.46%. Growth is driven by rising pharmaceutical research, CRISPR-Cas9 advances, personalized medicine demand, and vaccine R&D expansion. Rodents remain the dominant animal type, while key players include Charles River Laboratories, Eurofins Scientific, and The Jackson Laboratory.

A securities class action lawsuit has been filed against ARS Pharmaceuticals for allegedly providing false and misleading statements regarding the timeline for expanded insurance coverage of its epinephrine nasal spray product 'neffy' through CVS Caremark. The company allegedly stated coverage would begin July 1, 2026, while concealing material adverse facts about the actual timeline, causing investors to purchase securities at artificially inflated prices. The lead plaintiff deadline is October 5, 2026.

US to loan up to 40 million barrels of oil from SPR, last batch from global deal  Reuters

A securities class action lawsuit has been filed against ARS Pharmaceuticals, Inc. (SPRY) for allegedly providing false and misleading statements regarding the timeline for expanded insurance coverage of its epinephrine nasal spray product 'neffy' through CVS Caremark. The company allegedly misled investors about expected July 1, 2026 coverage, causing shareholders to purchase securities at artificially inflated prices. The lead plaintiff deadline is October 5, 2026.

Schall, Brown & Schwartz LLP announced a securities fraud class action lawsuit against ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) for making false and misleading statements regarding timeline issues related to CVS Caremark's addition of neffy to its formulary. The class period spans March 9, 2026 to June 24, 2026, with an October 5, 2026 deadline for investors to participate. Shareholders who suffered losses are encouraged to contact the firm regarding lead plaintiff appointments.

Rosen Law Firm announces class action securities lawsuits against ARS Pharmaceuticals (SPRY) and Datavault AI (DVLT), with October 5, 2026 deadline for investors to join. ARS Pharmaceuticals is accused of providing misleading statements regarding insurance coverage expansion timeline for its epinephrine spray product neffy through CVS Caremark, allegedly causing investors to purchase shares at artificially inflated prices.

Pomerantz Law Firm has filed a class action lawsuit against ARS Pharmaceuticals (NASDAQ: SPRY) alleging securities fraud. The lawsuit was triggered after ARS announced on June 24, 2026, that it failed to secure expanded insurance coverage for its epinephrine nasal spray product 'neffy' through CVS Caremark by the July 1 deadline. The announcement caused ARS's stock to plummet 23.91% to $8.02 per share on June 25, 2026. Investors have until October 5, 2026, to request appointment as Lead Plaintiff.

A securities class action lawsuit has been filed against ARS Pharmaceuticals (SPRY) for allegedly providing false and misleading statements regarding the timeline for expanded insurance coverage of its epinephrine nasal spray product 'neffy' through CVS Caremark. The company allegedly misled investors about a July 1, 2026 coverage start date, causing shareholders to purchase securities at artificially inflated prices. The lead plaintiff deadline is October 5, 2026.

A securities class action lawsuit has been filed against ARS Pharmaceuticals, Inc. (SPRY) for allegedly providing misleading statements to investors regarding the timeline for expanded insurance coverage of its epinephrine nasal spray product 'neffy' through CVS Caremark. The company reportedly made confident statements about July 1, 2026 coverage while concealing material adverse facts, causing investors to purchase securities at artificially inflated prices. The lead plaintiff deadline is October 5, 2026.

Pomerantz Law Firm has filed class action lawsuits against ARS Pharmaceuticals, Inc. and other companies for alleged securities fraud. ARS's stock fell 23.91% after the company failed to secure expanded insurance coverage for its epinephrine nasal spray (neffy) through CVS Caremark by the July 1, 2026 deadline. Investors have until October 5, 2026 to join the class action.

Holzer & Holzer, LLC announces lead plaintiff deadlines for shareholder class action lawsuits against three companies: Pentair plc for alleged false statements regarding inventory destocking in its Pool channel (deadline October 2, 2026); Datavault AI Inc. for alleged misrepresentations about partnership value and trading activity (deadline October 5, 2026); and ARS Pharmaceuticals, Inc. for alleged false statements about insurance coverage timeline for its epinephrine nasal spray product (deadline October 5, 2026).

Schall, Brown & Schwartz LLP announced a securities fraud class action lawsuit against ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) for making false and misleading statements regarding timeline issues related to CVS Caremark's addition of neffy to its formulary. The class period spans March 9, 2026 to June 24, 2026, with a deadline of October 5, 2026 for investors to participate. The lawsuit alleges the company recklessly disregarded risks that could significantly impact insurance coverage guidance and commercialization of neffy.

The article compares AbbVie, a mature pharmaceutical company with stable cash flows and a growing immunology portfolio, against CRISPR Therapeutics, a clinical-stage biotech firm pioneering gene-editing therapies. AbbVie is recommended as the better choice for 2026 due to its profitability, strong free cash flow generation, and rising dividend, while CRISPR offers high-reward potential but faces significant cash burn and execution risks.

A securities class action lawsuit has been filed against ARS Pharmaceuticals, Inc. (SPRY) alleging that defendants made false and misleading statements regarding the timeline for expanded insurance coverage of its epinephrine nasal spray product 'neffy' through CVS Caremark. Investors who purchased securities between March 9, 2026 and June 24, 2026 may be eligible for compensation. The lead plaintiff deadline is October 5, 2026.

The article compares Amgen, an established pharmaceutical giant with $36.7B in revenue and a 2.60% dividend yield, against CRISPR Therapeutics, a gene-editing biotech pioneer with only $3.5M in revenue but groundbreaking CASGEVY therapy. While CRISPR offers high-growth potential, it remains unprofitable with significant losses. The author recommends Amgen for most investors seeking stability and predictable returns, though acknowledges CRISPR's improving commercial trajectory makes it a more compelling speculative opportunity than previously.

Rosen Law Firm is urging investors in ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) who purchased securities between March 9, 2026 and June 24, 2026 to join a class action lawsuit. The lawsuit alleges that company defendants made false and misleading statements regarding the expected timeline for CVS Caremark insurance coverage expansion for the company's epinephrine spray product, neffy, causing investors to purchase shares at artificially inflated prices. The deadline to file is October 5, 2026.

Rosen Law Firm is encouraging investors who purchased securities of ARS Pharmaceuticals (SPRY) between March 9, 2026 and June 24, 2026 to join a class action lawsuit. The firm alleges that ARS Pharmaceuticals provided false and misleading statements regarding the timeline for expanded insurance coverage of its epinephrine nasal spray product (neffy) through CVS Caremark, causing investors to purchase securities at artificially inflated prices. The lead plaintiff deadline is October 5, 2026.

CRISPR Therapeutics stock surged nearly 19% in August following strong Q2 earnings. The company's approved blood disorder treatment Casgevy saw 78% quarter-over-quarter sales growth to $76 million, and the FDA approved its label expansion for pediatric patients aged 2 and older. CRISPR also received a $10 million upfront payment from a licensing deal, significantly boosting revenue to $10.2 million and narrowing net losses compared to year-ago figures.

Rosen Law Firm is notifying investors of ARS Pharmaceuticals (SPRY) about a securities class action lawsuit with an October 5, 2026 lead plaintiff deadline. The lawsuit alleges that ARS Pharmaceuticals provided false and misleading statements regarding the timeline for expanded insurance coverage of its epinephrine nasal spray 'neffy' through CVS Caremark, causing investors to purchase securities at artificially inflated prices.

A securities class action lawsuit has been filed against ARS Pharmaceuticals, Inc. (SPRY) alleging that defendants made false and misleading statements regarding the timeline for expanded insurance coverage of its epinephrine nasal spray product 'neffy' through CVS Caremark. Investors who purchased securities between March 9, 2026 and June 24, 2026 may be entitled to compensation. The lead plaintiff deadline is October 5, 2026.

Rosen Law Firm is seeking lead plaintiffs for a securities class action lawsuit against ARS Pharmaceuticals, Inc. (SPRY) for allegedly providing false and misleading statements regarding insurance coverage timelines for its epinephrine nasal spray product 'neffy' with CVS Caremark. Investors who purchased securities between March 9, 2026 and June 24, 2026 may be eligible for compensation. The lead plaintiff deadline is October 5, 2026.

Rosen Law Firm is reminding investors who purchased ARS Pharmaceuticals securities between March 9, 2026 and June 24, 2026 of an October 5, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that ARS Pharmaceuticals provided false and misleading statements regarding the timeline for expanded insurance coverage of its epinephrine nasal spray product (neffy) through CVS Caremark, causing investors to purchase securities at artificially inflated prices.

A securities class action lawsuit has been filed against ARS Pharmaceuticals Inc. for allegedly providing misleading statements about expanded insurance coverage for its epinephrine nasal spray product neffy through CVS Caremark. The company failed to disclose risks that the July 1, 2026 coverage deadline might not be met. When the truth emerged on June 24, 2026, ARS stock declined over 23.9% in a single day.

Cathie Wood's Ark Investment Management holds $362 million in CRISPR Therapeutics across two ETFs. While known for gene-editing work like the FDA-approved Casgevy, the company is quietly developing CAR T-cell therapies that could address a market projected to exceed $60 billion annually by 2034. CRISPR's off-the-shelf CAR T approach using donor cells could reduce costs compared to patient-specific treatments, positioning it competitively despite being in early trial stages.

The article compares two biotech companies: CRISPR Therapeutics, which has achieved its first gene-editing product approval for sickle cell disease but faces significant losses and customer concentration risks, versus Viking Therapeutics, a clinical-stage company targeting the obesity and metabolic disorder markets with no approved products yet. While both are highly speculative, the author favors CRISPR due to its existing revenue and approved treatment, despite Viking's potentially larger market opportunity.

The CRISPR-based drug development platforms market is projected to grow at a CAGR of 11.4%, reaching USD 0.79 billion by 2031 from USD 0.46 billion in 2026. Growth is driven by advancements in precision medicine, gene therapy expansion, and increased biotech investments, though regulatory challenges and high development costs remain constraints.

SPR, a medical device company specializing in peripheral nerve stimulation (PNS) for pain management, has been named a Top Workplace by Northeast Ohio Top Workplaces for the fifth consecutive year. The recognition reflects the company's strong workplace culture amid significant growth, including doubled employee count and surpassed 50,000 patients treated with its SPRINT PNS System. SPR announced that Medtronic intends to acquire the company, a partnership expected to expand the SPRINT PNS reach to more patients.